Table 4.
Multivariate analyses of recurrence‐free survival and disease‐specific survival in this cohort
| Variable | RFS | DSS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age | ||||
| ≤40 y | 1.00 | ‐ | 1.00 | ‐ |
| >40 y | 0.80 (0.67‐0.94) | 0.009 | 1.25 (0.93‐1.68) | 0.13 |
| Tumor size | ||||
| ≤2 cm | 1.00 | ‐ | 1.00 | ‐ |
| >2 cm | 1.55 (1.32‐1.82) | <0.001 | 1.74 (1.36‐2.22) | <0.001 |
| Lymph node | ||||
| Negative | 1.00 | ‐ | 1.00 | ‐ |
| Positive | 3.69 (3.18‐4.29) | <0.001 | 5.08 (4.05‐6.37) | <0.001 |
| Grade | ||||
| I | 1.00 | ‐ | 1.00 | ‐ |
| II | 1.37 (1.06‐1.78) | 0.02 | 1.94 (1.23‐3.08) | 0.005 |
| III | 1.49 (1.10‐2.03) | 0.01 | 2.18 (1.30‐3.65) | 0.003 |
| ER status | ||||
| Negative | 1.00 | ‐ | 1.00 | ‐ |
| Positive | 0.72 (0.56‐0.91) | 0.006 | 0.75 (0.45‐1.05) | 0.09 |
| PR status | ||||
| Negative | 1.00 | ‐ | 1.00 | ‐ |
| Positive | 0.73 (0.59‐0.90) | 0.003 | 0.51 (0.38‐0.70) | <0.001 |
| HER2 status | ||||
| Negative | 1.00 | ‐ | 1.00 | ‐ |
| Positive | 1.12 (0.95‐1.31) | 0.18 | 1.13 (0.90‐1.43) | 0.30 |
| Treatment | ||||
| No treatment | 1.00 | ‐ | 1.00 | ‐ |
| C vs no treatment | 1.11 (0.85‐1.47) | 0.44 | 0.83 (0.56‐1.24) | 0.36 |
| E vs no treatment | 1.28 (0.96‐1.70) | 0.09 | 0.97 (0.64‐1.47) | 0.87 |
| C + E vs no treatment | 1.17 (0.84‐1.63) | 0.35 | 0.83 (0.50‐1.37) | 0.46 |
| Mutation | ||||
| Non‐carriers | 1.00 | ‐ | 1.00 | ‐ |
| 16 DNA‐repair genes | 1.38 (1.00‐1.91) | 0.05 | 1.63 (1.04‐2.57) | 0.03 |
C, chemotherapy; CI, confidence interval; DSS, disease‐specific survival; E, endocrine therapy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; RFS, recurrence‐free survival.